Stock listing
NASDAQ:BBOT BridgeBio Oncology Therapeutics, Inc. Stock
Home listing (NASDAQ) of BridgeBio Oncology Therapeutics, Inc.
Follow BridgeBio Oncology Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:BBOT
$1.81 USD +0.01 (+0.3%)
Close on Nov 20, 2026
- Day range
- $1.79 – $1.94 USDNov 20, 2026
- Volume
- 450,960 sharesNov 20, 2026
- Market cap
- $145.3M USDAt the close on Nov 20, 2026 · price × 80.25M shares outstanding
- 52-week range
- $1.79 – $14.87 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $2.48M USDMedian day 505,700 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:BBOT · Home | $1.81 USD | +0.005 (+0.3%) | 450,960 | $1.87 | $1.94 | $1.785 | $1.805 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:BBOT · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.81 | +0.005 | +0.3% | $1.87 | $1.94 | $1.785 | 450,960 | |
| $1.805 | -0.135 | -7.0% | $1.91 | $1.96 | $1.79 | 576,715 | |
| $1.94 | -0.04 | -2.0% | $2.00 | $2.075 | $1.93 | 374,899 | |
| $1.98 | -0.16 | -7.5% | $2.13 | $2.226 | $1.97 | 801,455 | |
| $2.14 | -0.21 | -8.9% | $2.37 | $2.37 | $2.11 | 677,478 | |
| $2.35 | -0.21 | -8.2% | $2.50 | $2.68 | $2.00 | 778,968 | |
| $2.56 | +0.36 | +16.4% | $2.33 | $2.645 | $2.25 | 1,423,704 | |
| $2.20 | -0.10 | -4.3% | $2.29 | $2.34 | $2.185 | 486,662 | |
| $2.30 | +0.26 | +12.7% | $2.09 | $2.34 | $2.07 | 780,794 | |
| $2.04 | -0.13 | -6.0% | $2.19 | $2.25 | $1.985 | 686,343 | |
| $2.17 | -0.13 | -5.7% | $2.30 | $2.30 | $2.075 | 699,092 | |
| $2.30 | -0.02 | -0.9% | $2.33 | $2.39 | $2.22 | 451,527 | |
| $2.32 | +0.01 | +0.4% | $2.30 | $2.40 | $2.29 | 621,014 | |
| $2.31 | -0.31 | -11.8% | $2.64 | $2.64 | $2.295 | 579,578 | |
| $2.62 | -0.08 | -3.0% | $2.70 | $2.74 | $2.605 | 314,785 | |
| $2.70 | -0.10 | -3.6% | $2.81 | $2.948 | $2.69 | 357,036 | |
| $2.80 | +0.11 | +4.1% | $2.67 | $2.855 | $2.61 | 482,179 | |
| $2.69 | +0.05 | +1.9% | $2.65 | $2.725 | $2.51 | 1,755,926 | |
| $2.64 | -0.02 | -0.8% | $2.66 | $2.68 | $2.61 | 483,080 | |
| $2.66 | -0.19 | -6.7% | $2.83 | $2.83 | $2.60 | 737,317 | |
| $2.85 | +0.17 | +6.3% | $2.66 | $2.85 | $2.66 | 661,895 | |
| $2.68 | -0.04 | -1.5% | $2.71 | $2.855 | $2.66 | 942,242 | |
| $2.72 | -0.13 | -4.6% | $2.85 | $2.98 | $2.70 | 660,932 | |
| $2.85 | +0.03 | +1.1% | $2.84 | $2.90 | $2.79 | 695,643 | |
| $2.82 | -0.13 | -4.4% | $2.95 | $2.95 | $2.81 | 480,800 | |
| $2.95 | +0.045 | +1.5% | $2.90 | $3.304 | $2.86 | 473,900 | |
| $2.905 | -0.045 | -1.5% | $2.94 | $3.07 | $2.88 | 440,600 | |
| $2.95 | -0.31 | -9.5% | $3.24 | $3.34 | $2.93 | 505,700 | |
| $3.26 | -0.05 | -1.5% | $3.31 | $3.37 | $3.23 | 234,000 | |
| $3.31 | -0.11 | -3.2% | $3.43 | $3.50 | $3.295 | 472,000 | |
| $3.42 | -0.02 | -0.6% | $3.43 | $3.43 | $3.27 | 566,200 | |
| $3.44 | -0.06 | -1.7% | $3.46 | $3.57 | $3.36 | 321,300 | |
| $3.50 | -0.10 | -2.8% | $3.60 | $3.72 | $3.48 | 659,700 | |
| $3.60 | -0.29 | -7.5% | $3.88 | $3.88 | $3.575 | 481,600 | |
| $3.89 | -0.05 | -1.3% | $3.97 | $4.045 | $3.88 | 486,000 | |
| $3.94 | -0.16 | -3.9% | $4.05 | $4.10 | $3.82 | 1,363,700 | |
| $4.10 | +0.18 | +4.6% | $3.94 | $4.15 | $3.875 | 736,300 | |
| $3.92 | +0.11 | +2.9% | $3.83 | $4.02 | $3.80 | 537,400 | |
| $3.81 | -0.14 | -3.5% | $3.91 | $3.925 | $3.79 | 476,600 | |
| $3.95 | -0.04 | -1.0% | $4.00 | $4.00 | $3.89 | 523,500 | |
| $3.99 | -0.17 | -4.1% | $4.15 | $4.17 | $3.90 | 656,600 | |
| $4.16 | -0.50 | -10.7% | $4.61 | $4.70 | $4.05 | 539,600 | |
| $4.66 | 0.00 | 0.0% | $4.63 | $4.81 | $4.60 | 509,100 | |
| $4.66 | -0.11 | -2.3% | $4.84 | $4.84 | $4.594 | 468,700 | |
| $4.77 | -0.12 | -2.5% | $4.86 | $4.86 | $4.69 | 1,229,800 | |
| $4.89 | +0.13 | +2.7% | $4.84 | $5.10 | $4.84 | 415,400 | |
| $4.76 | -0.12 | -2.5% | $4.93 | $4.99 | $4.71 | 855,300 | |
| $4.88 | -0.17 | -3.4% | $5.01 | $5.015 | $4.72 | 629,200 | |
| $5.05 | +0.10 | +2.0% | $4.91 | $5.18 | $4.85 | 956,000 | |
| $4.95 | -0.57 | -10.3% | $5.53 | $5.616 | $4.90 | 1,630,900 | |
| $5.52 | -1.235 | -18.3% | $6.785 | $6.785 | $5.48 | 2,789,400 | |
| $6.755 | -2.105 | -23.8% | $8.86 | $8.86 | $6.295 | 1,498,900 | |
| $8.86 | -0.12 | -1.3% | $8.88 | $9.05 | $8.775 | 152,500 | |
| $8.98 | +0.08 | +0.9% | $8.80 | $9.06 | $8.65 | 117,600 | |
| $8.90 | +0.01 | +0.1% | $8.93 | $9.041 | $8.66 | 139,200 | |
| $8.89 | +0.07 | +0.8% | $8.81 | $9.185 | $8.73 | 238,900 | |
| $8.82 | +0.02 | +0.2% | $8.70 | $8.90 | $8.535 | 145,600 | |
| $8.80 | +0.06 | +0.7% | $8.72 | $9.195 | $8.41 | 476,000 | |
| $8.74 | -0.44 | -4.8% | $9.16 | $9.16 | $8.69 | 195,000 | |
| $9.18 | -0.08 | -0.9% | $9.19 | $9.315 | $9.06 | 385,300 | |
| $9.26 | -0.11 | -1.2% | $9.36 | $9.47 | $9.04 | 247,200 | |
| $9.37 | +0.23 | +2.5% | $9.24 | $9.473 | $9.18 | 197,974 | |
| $9.14 | +0.06 | +0.7% | $9.10 | $9.358 | $8.80 | 338,518 | |
| $9.08 | 0.00 | 0.0% | $9.19 | $9.435 | $9.03 | 170,900 | |
| $9.08 | -0.52 | -5.4% | $9.55 | $9.78 | $9.08 | 203,300 |
- Ticker
- NASDAQ:BBOT
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 10, 2026
BBOT Reports Third Quarter 2026 Financial Results and Update on Corporate Progress
Latest deck · September 2026
Investor Presentation (September 2026)
Investor deck · 35 slides
Latest news
BBOT Reports Third Quarter 2026 Financial Results and Update on Corporate Progress
Nov 10, 2026
Closed $2.56 (+16.4%) on Nov 11, 2026
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Oct 12, 2026
Closed $2.95 (-9.5%) on Oct 13, 2026
BBOT Announces New BBO-8520 Data; Highlights Strategic Focus on 2L+ NSCLC BBO-8520 Combination as Well as BBO-11818 and BBO-10203 Combinations in KRAS-Mutant Cancers
Sep 8, 2026
Closed $6.76 (-23.8%) on Sep 9, 2026
BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress
Aug 11, 2026
Closed $9.42 (+2.4%) on Aug 12, 2026
BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress
May 12, 2026
Closed $8.08 (-0.6%) on May 13, 2026
BBOT Presents Preclinical Data Demonstrating pan-KRAS Inhibitor BBO-11818 Has Robust Anti-Tumor Activity in KRAS-Mutant Preclinical Models at the AACR Annual Meeting 2026
Apr 22, 2026
Closed $8.97 (+1.1%) on Apr 23, 2026
BBOT Presents Preclinical Data Showing RAS: PI3Kα Breaker BBO-10203 Inhibits PI3Kα/AKT Signaling in HER2AMP Models at the AACR Annual Meeting 2026
Apr 21, 2026
Closed $8.87 (-6.2%) on Apr 22, 2026
BBOT Granted U.S. FDA Fast Track Designation for BBO-11818 for the Treatment of Adult Patients with Advanced KRAS-Mutant Pancreatic Ductal Adenocarcinoma
Apr 20, 2026
Closed $9.46 (+2.2%) on Apr 21, 2026
BBOT Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026
Mar 18, 2026
Closed $9.05 (+1.9%) on Mar 19, 2026
BridgeBio Oncology Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 17 in the last 12 months · 27 in all · newest Nov 10, 2026 · oldest 2025
- Decks
- 5 decks · latest September 2026
Where BridgeBio Oncology Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:BBOT · Home listing · This page | NASDAQ | United States | USD |
| BOATS:BBOT | BOATS | United States | USD |
| BIVA:BBOT | BIVA | Mexico | MXN |
| BMV:BBOT | BMV | Mexico | MXN |
Valuation
Price/book 0.5× against a median of 1.7×: 2nd lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$46.23M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.5×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.49
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| BridgeBio Oncology Therapeutics, Inc. · NASDAQ:BBOT | US$145.3M | −US$46.23M | n/a | n/a | n/a | 0.5× | n/a | 0.0× | 1.49 |
| Eledon Pharmaceuticals, Inc. · NASDAQ:ELDN | US$150.3M | US$80.67M | n/a | n/a | n/a | 4.9× | n/a | 0.0× | 1.95 |
| Veraxa Biotech AG · NASDAQ:VRXA | US$147.1M | US$145.1M | n/a | 5,202× | n/a | n/a | n/a | n/a | 1.11 |
| ProQR Therapeutics N.V. · NASDAQ:PRQR | US$146.8M | US$49.73M | n/a | 2.2× | n/a | 2.0× | −210.7% | 0.2× | 1.73 |
| ALX Oncology Holdings Inc. · NASDAQ:ALXO | US$146.6M | US$9.57M | n/a | n/a | n/a | 1.2× | n/a | 0.1× | 0.68 |
| Bicycle Therapeutics PLC · NASDAQ:BCYC | US$146.1M | −US$323.8M | n/a | −3.9× | n/a | 0.3× | −169.8% | 0.0× | 1.59 |
| TYK Medicines, Inc. Class H · HKEX:2410 | US$144.9M | US$137.1M | n/a | n/a | n/a | 3.7× | n/a | 0.6× | n/a |
| Sutro Biopharma, Inc. · NASDAQ:STRO | US$142.8M | US$259.6M | n/a | 5.8× | n/a | n/a | −344.2% | n/a | 1.14 |
| VISEN Pharmaceuticals · HKEX:2561 | US$140.7M | US$91.40M | n/a | 29.9× | n/a | 1.4× | n/a | 0.3× | n/a |
| Protara Therapeutics, Inc. · NASDAQ:TARA | US$140.4M | US$15.77M | n/a | n/a | n/a | 1.0× | n/a | 0.0× | 1.12 |
| Cloudbreak Pharma, Inc. · HKEX:2592 | US$140.4M | US$82.03M | n/a | n/a | n/a | 2.3× | n/a | 0.0× | n/a |
| Median of the others | US$145.5M | US$81.35M | 5.8× | 1.7× | −210.7% | 0.1× | 1.14 |
Forecasts
8 strong buy · 4 buy · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.
- Price target
- 23.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -1.93 · 3 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Pedro J. Beltran | Chief Executive Officer |
| Uneek Mehra | Chief Financial Officer |
| Idan Elmelech | Chief Operating Officer |
| Heather Armstrong | Head of Investor Relations BBOT |
| Aaron Chan | Vice President, Legal |
| Bin Wang | Senior Vice President, Drug Discovery |
| Chunmei Ji | Vice President, Head of Toxicology |
| Daniel Watson | Senior Vice President, Chemistry, Manufacturing, and Controls |
| Foster Gonsalves | Vice President, Early Development |
| Hua Gong | Vice President, Translational Medicine |
| Joon Whan Rhee | Vice President, Clinical Development |
| Kerstin Sinkevicius | Vice President, Pharmacology |
| Marc Cobo | Vice President of Finance and Controller |
| Rui Xu | Senior Vice President, Drug Discovery |
| Sunyoung Lee | Vice President, Regulatory Affairs |
| Frank McCormick | Cofounder, Non-Executive Director |
| Neil Kumar | Executive Chairman |
| Yong Ben | Chief Medical and Development Officer |
Board
| Director | Role |
|---|---|
| Jake Bauer | Chairman |
| Neil Kumar | Executive Chairman |
| Bihua Chen | Director |
| Frank McCormick | Cofounder, Non-Executive Director |
| Peter F. Lebowitz | Director |
| Praveen Tipirneni | Non-Executive Director |
| Raymond Kelleher | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 10, 2026 · After close | +16.4% |
| Q2 2026 | Aug 11, 2026 · After close | +2.4% |
| Q1 2026 | May 13, 2026 | +4.7% |
| Q4 2025 | Mar 5, 2026 · After close | +5.4% |
| Q3 2025 | Nov 12, 2025 · After close | −2.0% |
| Q2 2025 | Sep 3, 2025 | +5.2% |
| Q1 2025 | May 28, 2025 | |
| Q4 2024 | Mar 11, 2025 |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (September 2026) | Investor deck | 35 slides | September 2026 |
| SPAC Merger (February 2025) | SPAC merger | 50 slides | Feb 28, 2025 |
| ENA 2024 | Conference | 19 slides | 2024 |
| Technical Presentation (September 2023) | Technical | 30 slides | September 2023 |
| 5th Annual RAS-Targeted Drug Development Summit (September 2023) | Conference | 28 slides | September 2023 |
IPO
Went public as Helix Acquisition Corp. II, a blank check company (SPAC). Priced at US$10.00 a share on Feb 8, 2024.
- Price
- US$10.00 a share
- Shares offered
- 16,000,000 Class A ordinary shares
- Offering size
- US$160 million
- Underwriters' option
- Up to 2,400,000 more shares
- Listing
- HLXB on the Nasdaq Global Market
- Underwriter
- Leerink Partners
- Shares delivered
- On or about Feb 13, 2024
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Dec 20, 2023 |
| Filed publicly | Jan 18, 2024 |
| Amended twice | Newest Feb 7, 2024 |
| Shares registered with an exchange | Feb 8, 2024 |
| Declared effective by the SEC | Feb 8, 2024 |
| Final prospectus, with the price | Feb 13, 2024 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Feb 13, 2024 |
| EFFECT · Notice that a registration is effective | Feb 8, 2024 |
| S-1MEF · Registration of more shares for the same offering | Feb 8, 2024 |
| CERT · Exchange's certificate of listing | Feb 8, 2024 |
| 8-A12B · Registration of shares for listing on an exchange | Feb 8, 2024 |
| CORRESP · Letter to the SEC | Feb 7, 2024 |
| CORRESP · Letter to the SEC | Feb 7, 2024 |
| S-1/A · Registration statement, amended | Feb 7, 2024 |
| CORRESP · Letter to the SEC | Feb 6, 2024 |
| UPLOAD · Letter from the SEC | Feb 6, 2024 |
All 17 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Feb 2, 2024 |
| S-1/A · Registration statement, amended | Feb 2, 2024 |
| UPLOAD · Letter from the SEC | Jan 23, 2024 |
| CORRESP · Letter to the SEC | Jan 18, 2024 |
| S-1 · Registration statement | Jan 18, 2024 |
| UPLOAD · Letter from the SEC | Jan 10, 2024 |
| DRS · Draft registration statement | Dec 20, 2023 |
Open IPO · From the cover of the final prospectus (424B4) filed Feb 13, 2024
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | ||
| Cost of revenue | 610.0K | ||||
| Gross profit | -610.0K | ||||
| Research and development | 121.2M | 73.1M | 56.3M | ||
| Selling, general and administrative | 24.6M | 7.76M | 8.48M | 3.52K | 74.3K |
| Operating income | -145.8M | -80.9M | -41.7K | -3.52K | -43.4K |
| Depreciation and amortization | 280.0K | 208.0K | 92.0K | 3.52K | 74.3K |
| EBITDA | -145.5M | -80.7M | 50.3K | 0 | 31.0K |
| Income before tax | -134.0M | -74.3M | -64.7M | -3.52K | -43.4K |
| Income tax | 0 | 0 | |||
| Net income | -134.0M | -74.3M | -41.7K | -3.52K | -43.4K |
| Earnings per share, basic | -4.30 | -5,756.41 | -0.00 | -0.00 | -0.00 |
| Earnings per share, diluted | -4.30 | -5,756.41 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cash and equivalents | 373.7M | 30.9M | 0 | ||
| Short-term investments | 51.8M | 124.8M | 0 | ||
| Receivables | 386.0K | ||||
| Current assets | 432.4M | 158.7M | 3.94M | ||
| Property, plant and equipment | 956.0K | 490.0K | |||
| Total assets | 448.4M | 164.3M | 332.9K | 144.6K | 144.3K |
| Accounts payable | 1.37M | 3.07M | 575.0K | ||
| Current liabilities | 35.0M | 19.6M | 396.5K | 166.5K | 162.6K |
| Total debt | 2.77M | 70.1K | 43.1K | 37.0K | |
| Total liabilities | 37.3M | 19.6M | 396.5K | 166.5K | 162.6K |
| Shareholders' equity | 411.1M | -178.6M | -115.6M | -21.9K | -18.4K |
| Shares outstanding | 80.0M | 28.4K | 80.0M | 20.5M | 20.5M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cash from operations | -113.9M | -55.0M | -52.1M | ||
| Capital spending | -606.0K | -49.0K | -414.0K | 0 | 0 |
| Free cash flow | -114.5M | -55.1M | -52.5M | ||
| Cash from investing | 73.3M | -120.5M | -2.82M | ||
| Cash from financing | 383.4M | 206.3M | 55.1M | ||
| Change in cash | 342.8M | 30.7M | 225.0K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 20, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 18, 2026 | Other filings | SEC |
| 4 · Change in ownership | Nov 17, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 13, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 13, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 10, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 10, 2026 | Results | SEC |
| 8-K · Current report | Nov 5, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Oct 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 5, 2026 | Insider trade | SEC |
All 192 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Oct 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 14, 2026 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Sep 11, 2026 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Sep 9, 2026 | Other filings | SEC |
| 8-K · Current report | Sep 8, 2026 | Current report | SEC |
| S-3 · Registration statement | Sep 1, 2026 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Sep 1, 2026 | Offer document | SEC |
| 424B3 · Prospectus | Aug 11, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 11, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 11, 2026 | Results | SEC |
| 4 · Change in ownership | Jul 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 6, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jul 6, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 6, 2026 | Insider trade | SEC |
| 424B3 · Prospectus | Jun 22, 2026 | Offer document | SEC |
| 8-K · Current report | Jun 22, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 424B3 · Prospectus | May 13, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | May 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 12, 2026 | Results | SEC |
| 4 · Change in ownership | May 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 12, 2026 | Insider trade | SEC |
| 424B3 · Prospectus | May 6, 2026 | Offer document | SEC |
| 4 · Change in ownership | May 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 5, 2026 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | May 5, 2026 | Other filings | SEC |
| POS AM · Amendment to an effective registration | Apr 30, 2026 | Offer document | SEC |
| 3 · Initial statement of ownership | Apr 30, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 30, 2026 | Insider trade | SEC |
| 424B3 · Prospectus | Apr 29, 2026 | Offer document | SEC |
| 8-K · Current report | Apr 29, 2026 | Management or board change | SEC |
| ARS · Annual report to shareholders | Apr 28, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 28, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 28, 2026 | Meeting notice | SEC |
| 424B3 · Prospectus | Apr 22, 2026 | Offer document | SEC |
| 8-K · Current report | Apr 22, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Mar 26, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 26, 2026 | Insider trade | SEC |
| 424B3 · Prospectus | Mar 26, 2026 | Offer document | SEC |
| 8-K · Current report | Mar 26, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Mar 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 12, 2026 | Insider trade | SEC |
| 424B3 · Prospectus | Mar 6, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 5, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 5, 2026 | Results | SEC |
| 424B3 · Prospectus | Jan 7, 2026 | Offer document | SEC |
| 424B3 · Prospectus | Jan 7, 2026 | Offer document | SEC |
| 8-K · Current report | Jan 7, 2026 | Current report | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Jan 2, 2026 | Offer document | SEC |
| 4 · Change in ownership | Dec 12, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 13, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2025 | Results | SEC |
| 4 · Change in ownership | Oct 16, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Oct 10, 2025 | Offer document | SEC |
| 4 · Change in ownership | Oct 6, 2025 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Sep 11, 2025 | Other filings | SEC |
| 424B3 · Prospectus | Sep 10, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Sep 8, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Sep 3, 2025 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Sep 3, 2025 | Big-stake notice | SEC |
| S-1 · Registration statement | Aug 29, 2025 | Offer document | SEC |
| 4 · Change in ownership | Aug 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 28, 2025 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Aug 20, 2025 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 18, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D · Big-stake notice | Aug 18, 2025 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Aug 18, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 18, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 18, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 18, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 18, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 18, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 18, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 18, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 18, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 18, 2025 | Insider trade | SEC |
| POS AM · Amendment to an effective registration | Aug 14, 2025 | Offer document | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Aug 13, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 13, 2025 | Insider trade | SEC |
| 8-K · Current report | Aug 12, 2025 | Acquisition or disposal | SEC |
| 3 · Initial statement of ownership | Aug 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 11, 2025 | Insider trade | SEC |
| 8-K · Current report | Aug 6, 2025 | Current report | SEC |
| 425 | Aug 4, 2025 | Other filings | SEC |
| 8-K · Current report | Aug 4, 2025 | Meeting outcome | SEC |
| 10-Q · Quarterly report | Aug 1, 2025 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 30, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 24, 2025 | Big-stake notice | SEC |
| 424B3 · Prospectus | Jul 21, 2025 | Offer document | SEC |
| 425 | Jul 21, 2025 | Other filings | SEC |
| 425 | Jul 11, 2025 | Other filings | SEC |
| 8-K · Current report | Jul 11, 2025 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Jul 11, 2025 | Other filings | SEC |
| 424B4 · Prospectus | Jul 10, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jul 9, 2025 | Other filings | SEC |
| S-4/A · Registration statement, amended | Jul 9, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jul 1, 2025 | Other filings | SEC |
| S-4/A · Registration statement, amended | Jul 1, 2025 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Jun 27, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jun 20, 2025 | Other filings | SEC |
| S-4 · Registration statement | Jun 20, 2025 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Jun 11, 2025 | Other filings | SEC |
| DRSLTR · Letter to the SEC with a draft | May 30, 2025 | Other filings | SEC |
| DRS/A · Draft registration statement, amended | May 30, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | May 15, 2025 | Quarterly report | SEC |
| UPLOAD · Letter from the SEC | May 13, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 22, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 15, 2025 | Big-stake notice | SEC |
| DRSLTR · Letter to the SEC with a draft | Apr 14, 2025 | Other filings | SEC |
| DRS · Draft registration statement | Apr 14, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 10, 2025 | Annual report | SEC |
| 425 | Mar 6, 2025 | Other filings | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Mar 4, 2025 | Big-stake notice | SEC |
| 425 | Feb 28, 2025 | Other filings | SEC |
| 8-K · Current report | Feb 28, 2025 | Material contract | SEC |
| 425 | Feb 28, 2025 | Other filings | SEC |
| 8-K · Current report | Feb 28, 2025 | Current report | SEC |
| 3 · Initial statement of ownership | Feb 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 10, 2025 | Insider trade | SEC |
| 8-K · Current report | Feb 10, 2025 | Management or board change | SEC |
| 10-Q · Quarterly report | Nov 14, 2024 | Quarterly report | SEC |
| SC 13G · Big-stake notice | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 8, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Oct 22, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 14, 2024 | Quarterly report | SEC |
| 10-Q · Quarterly report | May 15, 2024 | Quarterly report | SEC |
| SC 13G · Big-stake notice | Feb 23, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 23, 2024 | Big-stake notice | SEC |
| SC 13D · Big-stake notice | Feb 20, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Feb 20, 2024 | Current report | SEC |
| SC 13G · Big-stake notice | Feb 15, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Feb 14, 2024 | Material contract | SEC |
| 4 · Change in ownership | Feb 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2024 | Insider trade | SEC |
| 424B4 · Prospectus | Feb 12, 2024 | Offer document | SEC |
| 3 · Initial statement of ownership | Feb 9, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 9, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 9, 2024 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Feb 9, 2024 | Other filings | SEC |
| S-1MEF · Registration of more shares for the same offering | Feb 8, 2024 | Offer document | SEC |
| 3 · Initial statement of ownership | Feb 8, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 8, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 8, 2024 | Insider trade | SEC |
| CERT · Exchange's certificate of listing | Feb 8, 2024 | Other filings | SEC |
| 8-A12B · Registration of shares for listing on an exchange | Feb 8, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Feb 7, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Feb 7, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Feb 6, 2024 | Other filings | SEC |
| S-1/A · Registration statement, amended | Feb 6, 2024 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Feb 6, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Feb 2, 2024 | Other filings | SEC |
| S-1/A · Registration statement, amended | Feb 2, 2024 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Jan 23, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 18, 2024 | Other filings | SEC |
| S-1 · Registration statement | Jan 18, 2024 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Jan 10, 2024 | Other filings | SEC |
| DRS · Draft registration statement | Dec 20, 2023 | Offer document | SEC |
Cap table
Built by 6ix from BridgeBio Oncology Therapeutics, Inc.’s releases · as of Nov 5, 2026
- Common shares
- 80,251,267
- Fully diluted
- 80,251,267
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 80,251,267 | Nov 5, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 5, 2026 | 80,251,267 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| John Schmid Other companies: BlossomHill Therapeutics, Inc. (Director · Since at least Aug 6, 2026); First Tracks Biotherapeutics, Inc. (Director · Since at least Apr 1, 2026); Helix Acquisition Corp. III (Director · Since at least Jan 22, 2026); Design Therapeutics, Inc. (Director · Since at least Mar 25, 2021); AnaptysBio, Inc. (Director · Since at least Feb 2, 2018); Xeris Biopharma Holdings, Inc. (Director · Oct 5, 2021 – Aug 12, 2024 · Past); MoonLake Immunotherapeutics (Director · Oct 19, 2020 – Oct 19, 2020 · Past); Poseida Therapeutics Inc (Director · Jul 9, 2020 – Jan 8, 2025 · Past); Neos Therapeutics Inc (Director · Jul 2, 2018 – Mar 19, 2021 · Past) | Director · Feb 8, 2024 – Feb 8, 2024 · Past |
| Mark McKenna Other companies: Helix Acquisition Corp. III (Director · Since at least Jan 22, 2026); NewAmsterdam Pharma Company N.V. (Director · Since at least Jul 16, 2024); Spyre Therapeutics, Inc. (Board Member · Since at least Feb 1, 2024); Apogee Therapeutics, Inc. (Director · Since at least Aug 17, 2023); Freenome, Inc. (Director · Jun 11, 2024 – Jun 11, 2024 · Past); Prometheus Biosciences Inc (Chairman, President and CEO, Director · Mar 11, 2021 – Jun 16, 2023 · Past); Bausch Health Companies Inc. (President, Salix · Aug 2, 2018 – Aug 19, 2019 · Past) | Director · Feb 8, 2024 – Feb 8, 2024 · Past |
| Bihua Chen Other companies: BlossomHill Therapeutics, Inc. (Director · Since at least Aug 6, 2026); Helix Acquisition Corp. III (Chairperson and CEO, Director · Since at least Jan 22, 2026); Biomea Fusion, Inc. (Director · Since at least Jun 11, 2025) | Director · Since at least Aug 11, 2025 |
| Praveen Tipirneni Other companies: Tectonic Therapeutic, Inc. (Director · Since at least Jun 20, 2024); Panacea Acquisition II Corp (Director · Apr 6, 2021 – Apr 6, 2021 · Past); Morphic Holding Inc (President and CEO, Director · Jun 26, 2019 – Aug 16, 2024 · Past) | Non-Executive Director · Since at least Aug 11, 2025 |
| Jake Bauer Other companies: Immunovant, Inc. (Director · Since at least Apr 18, 2025); Enliven Therapeutics, Inc. (Chairman of the Board of Directors · Since at least Feb 23, 2023) | Director · Since at least Aug 11, 2025 |
| Neil Kumar Other companies: Maze Therapeutics, Inc. (Director · Since at least Mar 27, 2026); BridgeBio Pharma, Inc. (Chief Executive Officer, Director · Since at least Nov 16, 2023) | Executive Chairman · Since at least Aug 11, 2025 |
| Uneek Mehra Other companies: 4D Molecular Therapeutics, Inc. (See Remarks · Sep 22, 2023 – Mar 6, 2025 · Past); Myovant Sciences Ltd (Principal Financial Officer · Sep 7, 2021 – Mar 10, 2023 · Past) | Chief Financial Officer · Since at least Aug 11, 2025 |
| Jake Bauer Other companies: Immunovant, Inc. (Board Member · Since at least Apr 9, 2026) | Chairman · Since at least Aug 11, 2025 |
| Marc Cobo Other companies: Tricida Inc (SVP, Finance & CAO · Jun 29, 2020 – Sep 10, 2020 · Past) | Vice President of Finance and Controller · Since at least Apr 21, 2026 |
| Nebojsa Obradovic Other companies: Helix Acquisition Corp. III (Chief Legal Officer · Since at least Jan 22, 2026) | Chief Legal Officer · Since at least Feb 8, 2024 |
All 29 people
| Person | Seat |
|---|---|
| Pedro J. Beltran Other companies: BridgeBio Pharma, Inc. (Chief Executive Officer, Idan Elmelech as Chief Operating Officer · Since at least Apr 22, 2026) | Chief Executive Officer · Since at least Aug 11, 2025 |
| Yong Ben Other companies: Corbus Pharmaceuticals Holdings, Inc. (Director · Since at least Mar 6, 2023) | Chief Medical and Development Officer · Since at least Aug 11, 2025 |
| Aaron Chan | Vice President, Legal · Since at least Nov 4, 2026 |
| Albert A Holman III | Director · Feb 8, 2025 – Feb 8, 2025 · Past |
| Bin Wang | Senior Vice President, Drug Discovery · Since at least Nov 4, 2026 |
| Chunmei Ji | Vice President, Head of Toxicology · Since at least Nov 4, 2026 |
| Daniel Watson | Senior Vice President, Chemistry, Manufacturing, and Controls · Since at least Nov 4, 2026 |
| Eli M Wallace | Chief Executive Officer, Director · Since at least Aug 11, 2025 |
| Foster Gonsalves | Vice President, Early Development · Since at least Nov 4, 2026 |
| Frank McCormick | Cofounder, Non-Executive Director · Since at least Mar 6, 2026 |
| Heather Armstrong | Head of Investor Relations BBOT · Since at least May 12, 2026 |
| Hua Gong | Vice President, Translational Medicine · Since at least Nov 4, 2026 |
| Idan Elmelech | Chief Operating Officer · Since at least Feb 28, 2025 |
| Joon Whan Rhee | Vice President, Clinical Development · Since at least Nov 4, 2026 |
| Kerstin Sinkevicius | Vice President, Pharmacology · Since at least Oct 13, 2025 |
| Peter F. Lebowitz | Director · Since at least Nov 4, 2026 |
| Raymond Kelleher | Director · Since at least Aug 11, 2025 |
| Rui Xu | Senior Vice President, Drug Discovery · Since at least Nov 4, 2026 |
| Sunyoung Lee | Vice President, Regulatory Affairs · Since at least Nov 4, 2026 |
Log in to ask 6ix AI your own questions about BridgeBio Oncology Therapeutics, Inc.